Dr Jaume Reventós is the director of the Bellvitge Biomedical Research Institute (Idibell) of the University of Barcelona.
He is the co-founder of Transbiomed and was previously head of the Research Unit in Biomedicine and Translational Oncology at the Vall d’Hebron Research Institute (VHIR).
Reventós founded the VHIR spin-off Transbiomed in 2007 alongside Andreas Doll, Miguel Abal and Raimon Forés. In 2013, the company developed a test for early diagnosis of prostate cancer and began research into biomarkers for ovarian cancer.
view this profile